๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Advanced Solid Tumors
Clinical trial register · South Korea

Advanced Solid Tumors Trials in South Korea, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 3364 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:49 UTC
3364
Studies in scope
all four open statuses
1829
Recruiting now
open to new participants
503
Lead sponsors
across recruiting studies
Top sites
Seoul 21 Seongnam-si 6 Seongnam 4 Cheongju-si 3 Goyang-si 3
Narrow the registerReset
Recruitment status
Phase
Site location
Seoul21 Seongnam-si6 Seongnam4 Cheongju-si3 Goyang-si3
All 19 locations
Target enrolment
to

Advanced Solid Tumors trials in South Korea

23 of 3364 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Recruiting
A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors
NCT07460375Advanced Solid Tumors
LigaChem Biosciences, Inc.
Phase 1/2
191
Seoul
2026-08
Recruiting
A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
NCT07524348Advanced Solid Tumors
Samsung Bioepis Co., Ltd.
Phase 1
149
Seoul
2026-03-23
Recruiting
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
NCT07262619Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer
Eikon Therapeutics
Phase 1/2
160
Suwon
2026-01-20
Recruiting
Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors
NCT07215637Advanced Solid Tumors, Metastatic Solid Tumors
Chong Kun Dang Pharmaceutical
Phase 1
60
Seoul
2025-10-16
Recruiting
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
NCT06818643Advanced Solid Tumors, Malignant Neoplasm
Merck Sharp & Dohme LLC
Phase 1/2
270
Seoul
2025-03-25
Active, closed
A Study of ZW191 in Participants With Solid Tumors
NCT06555744Advanced Solid Tumors
Zymeworks BC Inc.
Phase 1
145
Goyang-si, Seongnam-si, Seoul
2024-10-30
Recruiting
A Study of BG-C477 in Participants With Advanced Solid Tumors
NCT06596473Advanced Solid Tumors
BeOne Medicines
Phase 1
310
Seongnam-si, GangnamGu, SeodaemunGu, SongpaGu
2024-10-03
Active, closed
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
NCT06239467Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation
OnKure, Inc.
Phase 1
200
Incheon, Seoul
2024-02-26
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
NCT06004245Advanced Solid Tumors, Colorectal Cancer
Vividion Therapeutics, Inc.
Phase 1
280
Daegu, Gyeonggi-do, Seongnam-si, Seoul
2024-01-25
Recruiting
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
NCT05954312Advanced Solid Tumors
Vividion Therapeutics, Inc.
Phase 1
290
Goyang, Incheon, Seongnam, Seoul, Suwon
2023-07-28
Recruiting
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
NCT05541822Advanced Solid Tumors
Abion Inc
Phase 2
178
Goyang-si, Suwon, Dongjak, Seoul, Sinchon-dong, Cheongju-si, Incheon, Jinju
2023-01-17
Recruiting
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
NCT05277168Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
83
Busan, Cheongju-si, Gyeonggi-do, Seongnam, Seongnam-si, Seoul
2022-05-30
Active, closed
A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors
NCT05114759Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
176
Seoul
2022-01-04
Recruiting
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
NCT05067283Advanced Solid Tumors
Merck Sharp & Dohme LLC
Phase 1
830
Seoul
2021-12-17
Active, closed
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
NCT05029882Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer
AbbVie
Phase 1
520
Busan, Seongnam, Jinju, Cheongju-si, Seoul
2021-10-13
Active, closed
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
NCT04449874Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
Genentech, Inc.
Phase 1
498
Seongnam-si, Seoul
2020-07-29
Active, closed
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT04185883Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Amgen
Phase 1
610
Seoul
2019-12-17
Active, closed
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
NCT04058756Advanced Solid Tumors
Novartis Pharmaceuticals
Phase 1
120
Seoul
2019-10-30
Active, closed
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
NCT02671435Advanced Solid Tumors
MedImmune LLC
Phase 1/2
383
Seoul
2016-02-22
Rows per page Showing 1–23 of 23
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-south-korea/condition/advanced-solid-tumors

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,364 studies in total at the last sync on 26 Sep 2026, 19:49 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 23 of those studies listing the condition Advanced Solid Tumors.

How many Advanced Solid Tumors trials are recruiting in South Korea?

13 of the 23 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:49 UTC sync. A further 0 have not yet opened recruitment, 10 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Advanced Solid Tumors), 23 studies
PhaseStudiesRecruitingShare
Phase 116769.6%
Phase 1/25421.7%
Phase 2228.7%

Most active sponsors

Lead sponsors with the most studies (Advanced Solid Tumors)
Lead sponsorStudiesRecruiting
AbbVie20
Bayer21
Merck Sharp & Dohme LLC22
Vividion Therapeutics, Inc.22
Abion Inc11
Amgen10
AstraZeneca11
BeOne Medicines11
Chong Kun Dang Pharmaceutical11
Eikon Therapeutics11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.